Work

Abstract CT087: Narmafotinib (AMP945) in combination with gemcitabine and nab paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a phase 2a study: Interim analysis

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct087

Authors: Terrie-Anne Cock, Sarah Kinkel, Nicole Kruger, Charlotte Mulder, Ananda Sumitra, Marion Harris, Warren Joubert, Lara Lipton, Adnan Nagrial, Nick Pavlakis, Jin Won Kim, Choong-kun Lee, Do-Youn Oh, Joon Oh Park, Woo-Jin Lee, Jason Lickliter, Christopher Burns

Institutions: Epworth Hospital, Monash Health, Westmead Hospital, GenesisCare, Seoul National University Bundang Hospital, Severance Hospital, Seoul National University Hospital, Samsung Medical Center, National Cancer Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822332

Cites:

Cited by: 1

Related to: 10